Global Pegfilgrastim Biosimilar Market | PMI

News2 years ago

Source: Global Pegfilgrastim Biosimilar Market | PMI

Filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, is PEGylated to create Pegfilgrastim. Amgen Inc. originally introduced pegfilgrastim as Neulasta. Pegfilgrastim biosimilars were later introduced to the market. Pegfilgrastim is a supportive oncology medication used to treat neutropenia caused by chemotherapy and/or radiotherapy in cancer patients.

---